Althea Experiences Record Breaking Patient Growth

The Althea Group is rapidly approaching 4,000 patients in Australia, with approximately 35 new patients being added each business day during December.

This is great news for the Althea Group (ASX:AGH), as it represents a 46% increase on the previous month.  

In fact, as of 16 December there are now 3,688 patients in Australia who have been prescribed the company's medical cannabis products.

This growth was driven in part by the launch of its new full spectrum cannabis-derived extract oral oil, CBD100, which has seen exceptionally strong sales during the first 18 days since it became available for prescription.  

Business is great, with patient numbers, prescriber numbers and product sales all increasing at a healthy rate going into the holiday period. Althea CEO, Josh Fegan

There are also now 408 Australian Healthcare Professionals who currently prescribe Althea's medicinal cannabis products, significantly widening the company's potential patient base.

Aside from cannabidiol (CBD), the formulation used by Althea for CBD100 also contains small traces of terpenoids, flavonoids, and other cannabinoids—along with less than 1mg per ml of tetrahydrocannabinol (THC)—making it the company's most highly concentrated CBD medicinal cannabis product.

The product's full spectrum cannabinoid profile provides a distinct advantage over competing products, as in most cases they generally only use "purified" or "isolate" CBD.

Althea Group Holdings is a licensed producer, supplier, and exporter of pharmaceutical-grade medicinal #cannabis, and has already engulfed 20% of the Australian medicinal cannabis market since its ASX listing in 2018.

According to the CEO of Althea Group, sales of CBD100 have exceeded expectations, with 206 bottles already being sold. The product has also received strong response from doctors and patients alike, due to its affordability and potency.

"Althea CBD100 has launched successfully and we are already receiving positive feedback from doctors, patients and pharmacists about the product's efficacy and price point," Fegan said.

"In fact, many of our sales have come from prescribers switching their patients to Althea CBD100 from other brands."

Disclaimer: past performance is not an indicator of future performance

"Althea Concierge continues to underpin the Company's market leading strategy and we are well positioned to continue to improve patient access to medicinal cannabis treatment in Australia and beyond for many years to come," he said.

Althea currently remains on track to reach the 4,000-patient milestone before the conclusion of 2019, and it expected to continue enjoying strong prescription growth in future.

To learn more about Althea Group visit their Company HQ here.

Disclaimer: Past performance is not an indicator of future performance.

Get the Latest Marijuana News &
Content in your Inbox!

All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors

Hugo Gray
Hugo Gray

Hugo Gray is a Melbourne-based journalist with a body of work that covers a diverse range of topics, including immigration law, sex technology, and now the rapidly expanding cannabis industry.

Leave a Reply

Your email address will not be published. Required fields are marked *